FFAR out new targets for diabetes.
Dyslipidemia has long been associated with β cell dysfunction in the development of diabetes. Tang et al. (2015) have now revealed that β cell short-chain fatty acid receptors FFA2 and FFA3 are activated in an autocrine fashion and reduce insulin secretion in type 2 diabetes models.